International Experiences with New Presbyopia-Correcting IOLs

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, NY

Iqbal Ike K. Ahmed, MD

Assistant Professor, University of Toronto
Fellowship Director, Glaucoma and Anterior Segment Surgery Fellowship, University of Toronto
Research Director, Kensington Eye Institute, University of Toronto
Division Head, Ophthalmology, Trillium Health Partners, Mississauga, Ontario
Medical Director, Prism Eye Institute
Co-Medical Director, TLC Oakville
Toronto, Canada

Gerd U. Auffarth, MD, PhD, FEBO

Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
Director (Head), International Vision Correction Research Centre
Director (Head), David J. Apple Center for Ocular Pathology
University-Eye Clinic
Heidelberg, Germany

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allegro, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pharmaceutical, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, and Visus.

Iqbal Ike K. Ahmed, MD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aequus, Aerie Pharmaceuticals, Akorn, Alcon Vision, Allergan, Aquea Health, ArcScan, Bausch Health, Beaver Health, Beaver Visitec, Camras Vision, Carl Zeiss Meditec, CorNeat Vision, Ellex, ELT Sight, ElutiMed, Equinox, Genentech, Glaukos, Gore, InjectSense, Iridex, iStar, Ivantis, Johnson & Johnson Vision, KeLoTec, LayerBio, Leica, Long Bridge Medical, MicroOptx, MST Surgical, Mynosys, New World Medical, Ocular Instruments, Ocular Therapeutix, PolyActiva, Sanoculis, Santen, Science Based Health, Sight Sciences, Smartlens, Stroma, Thea, ViaLase, and Vizzario. SpeakerHonoraria: Alcon, Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, MST Surgical, Mundipharma. Research Grants: Aerie Pharmaceuticals, Alcon Vision, Allergan, Camras, Glaukos, Johnson & Johnson Vision, New World Medical, and Santen.

Gerd U. Auffarth, MD, PhD, FEBO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision. Lecture Fees: Biotech, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoyga, Kowa, Oculentis, Oculus, Rayner, Santen, and Sifi. Travel Fees: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoya, Kowa, Oculentis, Rayner, Santen, and Sifi. Research Grants: Acufocus, Johnson & Johnson Vision, Anew, Biotech, Carl Zeiss Meditec, Contamac, Hoya, Kowa, Oculentis, Oculus, PhysIOL, Rayner, Santen, and Sifi.

Eric D. Donnenfeld, MD

Moderator Partner, Ophthalmic Consultants of Long Island and Connecticut Clinical Professor of Ophthalmology, New York University Trustee, Dartmouth Medical School

Iqbal Ike K. Ahmed, MD

Assistant Professor, University of Toronto Fellowship Director, Glaucoma and Anterior Segment Surgery Fellowship, University of Toronto Research Director, Kensington Eye Institute, University of Toronto Division Head, Ophthalmology, Trillium Health Partners, Mississauga, Ontario Medical Director, Prism Eye Institute Co-Medical Director, TLC Oakville

Gerd U. Auffarth, MD, PhD, FEBO

Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital Director (Head), International Vision Correction Research Centre Director (Head), David J. Apple Center for Vision Research

Paul Harasymowycz, MD

Associate Professor, University of Montreal Medical Director Bellevue Ophthalmology Clinics and Montreal Glaucoma Institute

• Eric D. Donnenfeld, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant:  Allegro, Allergan , Alcon, Avellino Labs, Bausch & Lomb, CorneaGen, Covalent, CRST, BVI, Blephex, Dompe, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson, Kala, Katena, Lacripen, LensGen,  Mati Pharmaceuticals,  MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Therapeutics, Pfizer, Pogotec, Ocuhub, Omeros, PRN , RegenerEyes, ReTear, RPS, Shire, Strathspey  Crown, SUN, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, Visus, and Zeiss. Stock Shareholder: Avedro, CorneaGen, Covalent,  ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen , LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen,  Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey  Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus.
• Iqbal Ike K. Ahmed, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aequus, Aerie, Akorn, Alcon, Allergan, Aquea Health, ArcScan, Bausch Health, Beaver Health, Beaver Visitec, Camras Vision, Zeiss, CorNeat Vision, Ellex, ELT Sight, ElutiMed, Equinox, Genentech, Glaukos, Gore, InjectSense, Iridex, iStar, Ivantis, Johnson & Johnson Vision, KeLoTec, LayerBio, Leica, Long Bridge Medical, MicroOptx, MST Surgical, Mynosys, New World Medical, Ocular Instruments, Ocular Therapeutix, PolyActiva, Sanoculis, Santen, Science Based Health, Sight Sciences, Smartlens, Stroma, Thea, ViaLase, Vizzario; Speaker Honoraria: Alcon, Allergan, Zeiss, Johnson & Johnson Vision, MST Surgical, Mundipharma; Research Grants: Aerie, Alcon, Allergan, Camras, Glaukos, Johnson & Johnson Vision, New World Medical, Santen
• Gerd U. Auffarth, MD, PhD, FEBO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Johnson & Johnson Vision; Lecture Fees: Johnson & Johnson Vision, Biotech, Zeiss, Hoyga, Kowa, Oculentis, Oculus, Rayner, Santen, Sifi; Travel Fees: Alcon, Johnson & Johnson Vision, Zeiss, Hoya, Kowa, Oculentis, Rayner, Santen, Sifi; Research Grants: Acufocus, Johnson & Johnson Vision, Anew, Biotech, Zeiss, Contamac, Hoya, Kowa, Oculentis, Oculus, Physiol, Rayner, Santen, Sifi.
• Paul Harasymowycz, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Allergan, Alcon, Bausch Health, Novartis, Glaukos, Ivantis, Thea, Santen, Iridex, New World Medical, Johnson & Johnson Vision, Aequus; Grant/Research Support: Allergan, Bausch Health, Glaukos, Ivantis, Thea, and Johnson & Johnson Vision.